Abiopharma

🔍 Laumas Sandeep (Director)

Company: BioXcel Therapeutics, Inc. (BTAI)

Report Date: 2026-01-09

Detailed Transactions and Holdings:

• Acquired 17,000 shares of Stock Option (Right to Buy) at $2.01 per share (Derivative)
  Date: 2026-01-09 | Code: A | Expires: 2036-01-09 | equity_swap_involved: 0 | shares_owned_after: 17,000.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.